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Summary 4 
Objectives: To describe the clinical presentation, MRI findings and outcome in dogs with eosinophilic 5 
meningoencephalitis of unknown origin.  6 
Methods: A retrospective study was performed. Dogs were included if they had: complete medical records, 7 
complete neurological examination, MR imaging, cerebellomedullary cerebrospinal fluid sample consistent with 8 
eosinophilic pleocytosis and negative infectious disease testing.  9 
Results: 11 dogs were included with a median age of 22.0 months (range 7.6–92.0 months). Nine breeds were 10 
represented. Neurological abnormalities included obtundation (n=10), menace response deficits (n=9) 11 
proprioceptive deficits (n=7), ataxia (n=7) and seizures (n=2). Neuroanatomical localisation was multifocal (n=4), 12 
central vestibular system (n=4), diffuse forebrain (n=2), or left trigeminal/facial nerves (n=1). Seven dogs had a 13 
peripheral eosinophilia and all had an eosinophilic pleocytosis. Ten dogs had bilateral symmetrical lesions 14 
affecting the cortical gray matter that were hyperintense on T2-weighted and FLAIR images, iso- to hypointense 15 
on T1-weighted images with associated meningeal contrast enhancement. MRI findings were consistent with 16 
diffuse meningitis and atrophy or necrosis of cortical grey matter. One dog had increased contrast uptake of the 17 
left trigeminal nerve. Ten dogs receiving corticosteroids survived to discharge with 7 receiving additional 18 
cytarabine arabinoside. Median survival time was 762 days.  19 
Clinical significance: eosinophilic meningoencephalitis of unknown origin affects younger larger breed dogs with 20 
the majority having a suspected diffuse cerebrocortical meningitis and cortical (polio)encephalitis which can be 21 
identified on MRI. Response to immunosuppressive treatment is good in the medium to long term although further 22 
studies are required in this area. 23 
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Introduction 26 
Eosinophilic meningoencephalitis is diagnosed in humans and animals when neurological disease is associated 27 
with an eosinophilic pleocytosis (Williams 2008). In humans, an eosinophilia of greater than 10% of the total 28 
white blood cell count in the CSF is often used as a criterion for the diagnosis of eosinophilic meningoencephalitis 29 
(Kuberski 1981, Graeff-Teixeira et al. 2009). Eosinophilic meningoencephalitis in dogs can be associated with 30 
infectious and non-infectious causes. Infectious causes in dogs include Neospora caninum and less often 31 
Toxoplasma gondii (Bennett et al. 1997, Smith-Maxie et al. 1989). Other infectious causes include 32 
Angiostrongylus vasorum, Prototheca spp. Crytococcus spp., canine distemper virus, rabies and bacterial 33 
encephalitis (Smith-Maxie et al. 2008; Windsor et al. 2009). Non-infectious causes of eosinophilic 34 
meningoencephalitis include neoplasia, infarction, shunt placement, and trauma (Smith-Maxie et al. 2008; 35 
Windsor et al. 2009).  36 
 37 
Where no infectious or systemic causes have been identified, the term eosinophilic meningoencephalitis of 38 
unknown origin (eosinophilic MUO) is used. Eosinophilic MUO is considered a rare condition with only 30 canine 39 
cases reported to date and is now considered part of the spectrum of the canine non-infectious 40 
meningoencephalitides (Bennett et al. 1997; Salvadori et al. 2007; Smith-Maxie et al. 2008; Williams et al. 2008; 41 
Henke et al. 2009; Windsor et al. 2009; Granger et al. 2010; Olivier et al. 2010; Lowrie et al. 2013). Eosinophilic 42 
MUO affects multiple breeds and is suggested to be more common in young, male, large breed dogs. Reported 43 
clinical signs are variable and include mentation changes, ataxia, visual deficits, cervical hyperaesthesia and 44 
seizures (Bennett et al. 1997; Salvadori et al. 2007; Smith-Maxie et al. 2008; Williams et al. 2008; Henke et al. 45 
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2009; Windsor et al. 2009; Granger et al. 2010; Olivier et al. 2010). Descriptions of pathological findings and 46 
magnetic resonance imaging (MRI) characteristics of eosinophilic MUO are limited and range from a severe and 47 
diffuse eosinophilic meningitis with infiltration of the superficial cortex to multifocal granulomatous intra-axial 48 
mass lesions associated with eosinophilic infiltration of the parenchyma (Bennett et al. 1997; Salvadori et al. 49 
2007; Henke et al. 2009; Olivier et al. 2010). Eosinophilic MUO is hypothesised to be an immune-mediated 50 
condition, although the pathogenesis remains unknown (Dorta-Contreras & Reiber 1998; Williams et al. 2008). 51 
Treatment typically consists of immunosuppressive doses of corticosteroids, medication for potential infectious 52 
causes and supportive care. Reports of response to immunosuppressive therapy are limited, with some dogs 53 
experiencing resolution of clinical signs with corticosteroid treatment whilst others rapidly succumb despite 54 
aggressive treatment and supportive care (Bennett et al. 1997; Salvadori et al. 2007; Smith-Maxie et al. 2008; 55 
Williams et al. 2008; Henke et al. 2009; Windsor et al. 2009; Granger et al. 2010; Olivier et al. 2010). In 15-20% 56 
of reported cases diagnosed with eosinophilic meningoencephalitis, the clinical presentation, imaging findings 57 
and outcomes were potentially influenced by a possible infectious aetiology meaning these cases may not have 58 
been truly ‘idiopathic’ (Smith-Maxie et al. 2008; Williams et al. 2008; Henke et al. 2009). Given the diverse 59 
clinical and imaging findings, the aims of this study were to better describe the clinical presentation, diagnostic 60 
test results, imaging findings and treatment outcomes in dogs with eosinophilic MUO without evidence of 61 
infectious disease.  62 
  63 
 6 
Materials and methods 64 
Case selection and medical records review— The electronic medical records of the University of London Royal 65 
Veterinary College (RVC) Small Animal Referral Hospital and Ghent University (GU) were searched to identify 66 
dogs with suspected eosinophilic MUO that were diagnosed between January 1st 2000, and April 1st 2017. Search 67 
terms used included ‘eosinophilic meningoencephalitis’, ‘eosinophilic meningitis’, ‘eosinophilic pleocytosis’, 68 
‘eosinophilia’, ‘MUA’, ‘MUO’, ‘meningoencephalitis of unknown aetiology/etiology/origin’ and various 69 
combinations of these terms. Dogs were included if they had: 1) complete medical records available, 2) a complete 70 
neurological examination performed leading to a focal or multifocal intracranial neuroanatomical localization, 3) 71 
an eosinophilic pleocytosis on cerebrospinal fluid (CSF) analysis (Total nucleated cell count >5 cells/mm3 of CSF, 72 
>10% eosinophils on a 100 cell differential count), 4) and MRI of the brain (Granger et al. 2010). Dogs were 73 
excluded if: 1) clinical records or imaging studies were incomplete or not available for review, 2) meningomyelitis 74 
without clinical signs of intracranial involvement was diagnosed or 3) if no eosinophilic pleocytosis was found 75 
on CSF analysis (Bosch & Oehmichen 1978; Windsor et al. 2009). Information obtained from medical records 76 
included signalment, duration of clinical signs prior to diagnosis (time to presentation), treatment received prior 77 
to referral, general physical examination and neurological examination findings, neuroanatomical localisation and 78 
results of diagnostic tests including complete blood count (CBC), serum biochemistry profile, ancilliary tests for 79 
infectious agents and results of cisternal CSF analysis. Dogs were classified as small (<10 kg), medium (10–30 80 
kg) or large (>30 kg) breeds based on body weight (Cardy et al. 2015). Possible neuroanatomical localisations 81 
included diffuse forebrain, multifocal brain, central vestibular system or cranial nerves. The study was approved 82 
by the Royal Veterinary College Ethics and Welfare committee (protocol number URN 2017 1684-3).  83 
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 84 
Ancillary diagnostic tests 85 
For cisternal CSF analysis total nucleated cell count (TNCC), total protein (TP) concentration and nucleated cell 86 
differential count were recorded. TNCC was considered normal if the TNCC was less than 5 cells/mm3 (Di 87 
Terlizzi & Platt 2009, Dewey & da Costa 2016). Total protein concentration was considered normal for cisternal 88 
collection if <0.25 g/l (Di Terlizzi & Platt 2009, Dewey & da Costa 2016). Infectious disease testing on serum, 89 
CSF, or both was performed on a case-by-case basis and included: Cryptococcus latex agglutination Cryptococcal 90 
antigen test, Toxoplasma gondii IgG and IgM antibody, Neospora caninum immunofluorescent antibody test 91 
(IFA), PCR on CSF for Canine Distemper Virus, PCR on CSF for Toxoplasma gondii, PCR on CSF for Neospora 92 
caninum, SNAP 4Dx ELISA™ (Idexx) for Angiostrongylus vasorum, Ehrlichia canis, Borrelia burgdorferi, 93 
Anaplasma phagocytophilum and Anaplasma platys, Canine Distemper Virus IgG and IgM antibody, Angio 94 
Detect™ ELISA (Idexx) for Angiostrongylus vasorum. Faecal analysis was performed on three dogs for 95 
Angiostrongylus vasorum. All dogs had two or more tests for infectious agents performed.  96 
 97 
Diagnostic imaging 98 
MRI was performed under general anaesthesia with a permanent 1.5 T magnet (Intera, Philips Medical Systems, 99 
Eindhoven, the Netherlands) or a permanent 0.2 T magnet (Airis Mate, Hitachi Ltd, Tokyo, Japan). All images 100 
were reviewed by a board-certified radiologist using Osirix DICOM viewer (Osirix Foundation, V.5.5.2 Geneva, 101 
Switzerland). Studies included a minimum of T2-weighted (T2W) (repetition time (ms) (TR)/echo time (ms) (TE), 102 
3000/120), T1-weighted (T1W) (TR/TE, 400/8) and fluid attenuating inversion recovery (FLAIR) images of the 103 
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entire brain in a sagittal, transverse and dorsal plane. The T1W images were acquired before and after intravenous 104 
administration of paramagnetic contrast medium (0.1 mg/kg, gadoterate meglumine, Dotarem, Guerbet, Milton 105 
Keynes, UK). Variables recorded were lesion localisation and distribution, presence of parenchymal or meningeal 106 
contrast enhancement, presence of mass effect (brain herniation, midline shift, flattening of gyri/sulci), 107 
T1W/T2W/FLAIR signal intensity of the cerebral grey matter and size of the cerebral sulci/subarachnoid spaces.  108 
 109 
Treatment and follow-up  110 
The specific treatment protocol was recorded for all dogs (corticosteroids with or without cytosine arabinoside). 111 
Following admission, all dogs underwent at least one daily general physical examination and a complete 112 
neurological examination by a board-certified neurologist or a neurology resident during hospitalisation. 113 
Neurological examination results and response to treatment (improvement, deterioration, or static) were recorded 114 
in the medical records until discharge. Following discharge medical records were searched for the presence of a 115 
reexamination or owner/vet communication to confirm the dog was alive or dead and the current treatment as of 116 
April 1st 2017. For those dogs managed at their referring practices, the veterinary surgery was contacted directly 117 
(Thomas Cardy) by telephone for a verbal update on neurological status and current treatment. 118 
 119 
Statistical analysis  120 
Data analysis was performed using a standard statistical software package (SPSS: Statistical Package for the 121 
Social Sciences 22.0.1, SPSS). Non-parametric data were described using median and range. Comparisons 122 
between gender and neuter status were performed using a Chi-Squared test. Values of P<0·05 were considered 123 
 9 
significant. The relationship between variables was investigated using Pearson correlation coefficient. Preliminary 124 
analyses were performed to ensure no violation of the assumptions of normality, linearity and homoscedasticity. 125 
Survival analysis was performed using both a Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon test, 126 
resulting in median survival time (MST) calculation and a Kaplan-Meier survival curve. Survival was defined as 127 
time from diagnosis to death or euthanasia because of disease progression, or time from diagnosis to last follow-128 
up for dogs that were alive at time of data capture.  129 
   130 
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Results 131 
Signalment  132 
Initial database searches identified 27 dogs from the RVC and 4 dogs from GU. Eleven dogs met the inclusion 133 
criteria (9 from the RVC and 2 from GU). Four dogs (36.4%) were small breed, 4 dogs (36.4%) were medium 134 
sized and 3 dogs (27.2%) were large breed. Median bodyweight at presentation was 18.0 kg (Ranging from: 4.9 135 
kg–36.0 kg) and median age at presentation was 22.0 months (7.6–92.0 months). Six dogs (50%) were male, of 136 
which 2 were neutered, compared to 5 females (50%), of which 1 was neutered. No significant variation was 137 
found in either gender or neuter status. There were 9 breeds represented including 2 Flat-Coated Retriever and 2 138 
Welsh Terriers (Table 1). The 11 dogs included in the current study were predominantly younger, entire, large 139 
breed dogs as previously reported. (Bennett et al. 1997; Salvadori et al. 2007; Smith-Maxie et al. 2008; Williams 140 
et al. 2008; Henke et al. 2009; Windsor et al. 2009; Granger et al. 2010; Olivier et al. 2010). 141 
 142 
Clinical signs  143 
Median duration of clinical signs prior to diagnosis was 24 days (Ranging from: 2-78 days). The most common 144 
reasons for presentation included one or more of the following neurological signs: behavior changes (10 dogs, 145 
90.9%), ataxia (6 dogs, 54.5%), seizures (2 dogs, 18%), suspected blindness (3 dogs, 27.3%) and head tilt (2 dogs, 146 
18.2%). A single dog (9.1%) was referred for masticatory muscle atrophy and an inability to blink with the left 147 
eye. Three dogs (27.3%) were treated with oral prednisolone (0.35 - 1.8mg/kg/day) prior to referral for suspected 148 
otitis media/interna or suspected MUO. Median duration of corticosteroid treatment was 16.5 days (Ranging from: 149 
1–90 days) (Table 1).  150 
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Neurological examination  152 
Mentation was classified as abnormal in 10 dogs (90.9%) with all being described as mild to moderately obtunded. 153 
Seven dogs (63.6%) had ataxia affecting all limbs, 7 dogs (63.6%) had proprioceptive deficits (Table 1). Nine 154 
dogs (81.8%) had a reduced or absent menace response and 2 dogs (18.2%) had a reduced or absent pupillary 155 
light reflex (PLR) (Table 1). Two dogs (18.2%) presented with neurological signs consistent with a diffuse 156 
forebrain localisation, 4 dogs (36.4%) with a multifocal localisation, 4 dogs (36.4%) with a central vestibular 157 
system localisation and 1 dog (9.1%) with focal signs affecting the left trigeminal and left facial nerves (Table 1).   158 
 159 
Diagnostic findings  160 
One dog had a moderate neutrophilia 24.5 x 10^9/l (reference interval: 3.0 x 10^9/l - 11.5 x 10^9/l) suspected to 161 
be a result of chronic steroid treatment for presumed otitis interna/media. White blood cell counts of the remaining 162 
10 dogs were within normal limits (reference interval: 6-17.1 x 10^9/l). Nine dogs (81.8%) had a peripheral 163 
eosinophilia with a median cell number of 1.60 x 10^9/l (Ranging from: 0.2 x 10^9/l – 3.81 x 10^9/l, reference 164 
interval 0.0 x 10^9/l – 1.3 x 10^9/l), with all dogs having an increased proportion of eosinophils in the white blood 165 
cell count (Table 1). Cisternal CSF analysis demonstrated an eosinophilic pleocytosis in all dogs with a median 166 
TNCC of 671 WBC/mm3 (Ranging from: 6–5400 WBC/mm3, reference interval <5 WBC/mm3). The median 167 
differential cell count included 85% eosinophils (Ranging from: 12% - 95%, reference interval <1%). CSF median 168 
TP concentration was 0.61 mg/dl (Ranging from: 0.23-1.06 mg/dl, reference interval <25mg/dl). There was a 169 
significant positive correlation between eosinophil percentage in the CBC and eosinophil percentage in the CSF 170 
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(r = 0.683, p = 0.01). There was also a strong positive correlation between eosinophil numbers on CBC and the 171 
TNCC (r = 0.618, p = 0.032). 172 
 173 
Serology and/or PCR analysis of CSF for Toxoplasma gondii, Neospora caninum were available and negative in 174 
11 dogs (100%). PCR of CSF for canine distemper virus was available and negative in three dogs (27.3%). Five 175 
dogs (45.5%) tested negative for Angiostrongylus vasorum, Ehrlichia canis, Borrelia burgdorferi, Anaplasma 176 
phagocytophilum and Anaplasma platys with SNAP 4Dx ELISA™ (Idexx), serology for Cryptococcus spp. was 177 
negative in 3 dogs (27.3%). A further 8 dogs (72.7%) were negative for Angiostrongylus vasorum by Angio 178 
Detect™ (Idexx) and faecal analysis was normal for 3 dogs (27.3%). All 11 dogs tested negative for 179 
Angiostongylus vasorum by one or more tests.   180 
 181 
MRI findings  182 
MR imaging was performed between 3 and 40 hours after admission. In 10 dogs (90.9%) MR images 183 
demonstrated a T1W iso/hypointense to normal grey matter, T2W and FLAIR hyperintense signal affecting the 184 
cortical grey matter (Fig 1 a,b,c). Cerebral sulci appeared grossly enlarged with a reduction in the size of the 185 
cortical gyri (Fig 1a,c). In all 10 dogs the lesions were bilateral and symmetrical and confined to the cerebral 186 
cortex on MR images. T1W images retrieved after gadolinium contrast administration revealed diffuse contrast 187 
uptake affecting both the pachymeninges and leptomeninges in 10 dogs (Fig 1d, Table 1). Abnormalities detected 188 
in the MRI studies were felt to be most consistent with a diffuse meningitis and atrophy or necrosis of the cortical 189 
grey matter. In the remaining dog there was marked masticatory muscle atrophy with regions of T2W and FLAIR 190 
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hyperintensity within the masseter and temporalis muscles which also showed moderate contrast uptake (Fig 2). 191 
The left trigeminal nerve was T2W and FLAIR hyperintense compared to the right side and showed mild 192 
homogenous contrast enhancement (Fig 2). There was also a left mandibular lymphadenopathy. Significant MRI 193 
abnormalities could not be detected in the left facial nerve.  194 
 195 
Treatment 196 
All dogs survived initial general anaesthesia for MR imaging, whereafter 10 dogs (90.9%) received a single IV 197 
dose of dexamethasone (0.3–0.5 mg/kg) within hours of diagnosis. In 8 dogs (72.7%) initial dexamethasone 198 
treatment was followed by high dose oral prednisolone therapy (4 mg/kg/day) that was reduced after 48 hours (2 199 
mg/kg/day). In 2 dogs the initial starting dose of oral prednisolone was 2mg/kg/day and was reduced to 200 
1mg/kg/day after 48 hours. In 1 dog the initial oral prednisolone dose was 1mg/kg/day until results for 201 
Cryptococcus were returned negative, at which time the oral prednisolone dose was increased to 2mg/kg/day for 202 
6 weeks before dose reduction to 1mg/kg/day. The final dog did not receive steroid therapy and died the day after 203 
diagnosis (Case 11, Table 1). Dogs typically remained on the same dose of oral prednisolone for 3 weeks after 204 
which the dose was reduced by 50% depending on clinical progression. At the time of diagnosis 7 dogs (63.6%) 205 
received additional treatment with cytosine arabinoside, given as subcutaneous injections (50 mg/m2 SC every 12 206 
hours for 2 consecutive days). Dogs that started cytosine arabinoside treatment received a second course 3 weeks 207 
after initial treatment and treatment intervals were then typically extended by a week at each presentation 208 
depending on clinical progression. In 8 dogs a 14-day course of clindamycin was also provided (11-14mg/kg BID) 209 
until results for protozoal infectious disease testing returned negative. 210 
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Outcomes 212 
Ten dogs (90.9%) survived to discharge and one dog died of respiratory arrest the day after presentation (Table 213 
1). One dog was euthanised as a result of disease progression at 31 days post-diagnosis (Table 1). Two dogs were 214 
lost to follow-up at 60 days and 732 days, both were alive and considered to be neurologically improved at that 215 
time. One of the dogs lost to follow-up was receiving oral prednisolone only (1.5mg/kg/day) whilst the other dog 216 
was not receiving any immunosuppressive treatment (Table 1). Median survival time was 762 days (Ranging 217 
from: 31 to 3631 days). At the time of data capture 7 dogs were alive and had full follow-up information. Three 218 
dogs (42.8%) were considered to be neurologically normal and 3 dogs (42.8%) were considered improved but 219 
with mild deficits in menace response. The dog with left sided facial and trigeminal nerve deficits initially 220 
responded well to immunosuppressive treatment, but relapsed after the first prednisolone dose reduction at three 221 
weeks requiring a return to 2mg/kg/day oral prednisolone after which time it continued to improve (Table 1). Of 222 
the 7 dogs for which follow-up information was available 2 dogs were not receiving any immunosuppressive 223 
therapy, 2 dogs were receiving only cytarabine arabinoside (50 mg/m2 SC every 12 hours for 2 consecutive days) 224 
at eight weekly intervals, 2 dogs were receiving a combination of oral prednisolone (1-2mg/kg/day) and cytarabine 225 
arabinoside, 1 dog was receiving oral prednisolone only (0.5mg/kg, EOD) (Table 1). Case 5 had repeat MRI and 226 
cisternal CSF sampling performed 1173 days after diagnosis at the owner’s request. Neurological examination 227 
was within normal limits although the dog was felt by the owner to be slower to respond to commands and often 228 
seemed confused during normal daily life. CSF reported a TNCC of zero and a protein level of 0.13mg/dl 229 
(reference interval <25mg/dl). MRI findings included worsening vetriculomegaly, further widening of the 230 
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subarachnoid space, a reduction in size of the interthalamic adhesion and increased T2W hyperintense signal 231 
surrounding the cortical grey matter (Fig 3). These findings were felt to be consistent with a worsening diffuse 232 
meningitis and atrophy or necrosis of the cortical grey matter. 233 
  234 
 16 
Discussion 235 
Eosinophilic MUO has been sporadically reported in dogs and to date no clear consensus has been reached on the 236 
clinical presentation and MRI findings, making effective diagnosis and treatment challenging (Bennett et al. 1997; 237 
Salvadori et al. 2007; Smith-Maxie et al. 2008; Williams et al. 2008; Henke et al. 2009; Windsor et al. 2009; 238 
Granger et al. 2010; Olivier et al. 2010). The aim of this study was to better describe the clinical presentation, 239 
diagnostic test results, MRI findings and treatment outcomes of dogs with eosinophilic MUO without evidence 240 
of infectious disease. 241 
 242 
Eosinophils are secretory cells that provide a host defense against parasites but also have the potential to modulate 243 
inflammatory responses by producing cytokines and can contribute to chronic inflammation in a wide range of 244 
tissues (Lilliehook et al. 2000). Eosinophils differentiate from myeloid precursor cells and enter the circulation 245 
after maturation where they last for only minutes to hours and are rapidly recruited in response to chemokines 246 
into target tissues or inflammatory sites where they can survive for up to two weeks (Young et al. 2006). 247 
Eosinophils release neurotoxic proteins, such as eosinophilic cationic protein, major basic protein, and eosinophil-248 
derived neurotoxin and also produce reactive oxygen and nitrogen metabolites causing severe tissue damage 249 
(Oliveira & Lukacs 2003; Temkin et al. 2004). In the brain, neurons and myelinated axons are highly susceptible 250 
to eosinophilic-induced neurotoxicity (Williams et al. 2008).  251 
 252 
Consistent with previous reports the most common neurological examination findings included one or more of 253 
the following: mentation changes, seizures, proprioceptive deficits, visual deficits and reduced or absent menace 254 
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response consistent with a diffuse forebrain neuroanatomic localisation (Bennett et al. 1997; Salvadori et al. 2007; 255 
Smith-Maxie et al. 2008). Central vestibular system lesions have only previously been reported in one case of 256 
eosinophilic MUO, however in the current study four dogs showed neurological signs consistent with a central 257 
vestibular system localisation, including head tilt, nystagmus, mentation changes and vestibular ataxia (Henke et 258 
al. 2009). Although no lesions in the central vestibular system were detected on MR imaging in the current study, 259 
previously reported histopathological findings demonstrated an eosinophilic infiltrate throughout the brainstem 260 
and cerebellum which could account for the central vestibular system signs observed (Olivier et al. 2010). Nine 261 
dogs (81.8%) had a peripheral eosinophilia and all dogs had an increased proportion of eosinophils in the CBC 262 
(Table 1). This compares with previous reports where 51% of dogs had a peripheral eosinophilia. CSF analysis in 263 
all dogs showed an eosinophilic pleocytosis and increased TP concentration consistent with previous reports. Case 264 
2 is notable in that although all values were within the inclusion criteria the TNCC and differential cell count were 265 
lower than other cases (Table 1). This dog is unique in that it had received a 90 day tapering dose of corticosteroids 266 
prior to diagnosis and it is believed that the low TNCC, in comparison to the other cases, is reflective of a response 267 
to immunosuppressive corticosteroid treatment. 268 
 269 
MRI findings have previously been reported in 16 dogs with presumed eosinophilic meningoencephalitis of 270 
unknown origin and were considered normal in 6 dogs (37.5%). Two dogs (12.5%) had bilateral, symmetrical 271 
cortical atrophy and diffuse meningeal contrast uptake (Salvadori et al. 2007; Henke et al. 2009; Windsor et al. 272 
2009). In the current study 10 dogs (90.9%) demonstrated a T2W and FLAIR hyperintense signal affecting the 273 
cortical grey matter, T1W iso/hypointense to normal grey matter, with enlarged cerebral sulci, a reduction in 274 
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cortical gyri and diffuse meningeal contrast uptake (Fig 1). These MRI findings are identical to previous case 275 
reports where the accompanying histopathology was consistent with a severe eosinophilic and macrophagic 276 
inflammation resulting in a diffuse meningitis and atrophy or necrosis of the cortical grey matter (Salvadori et al. 277 
2007; Henke et al. 2009; Windsor et al. 2009). Based on the histopathological findings reported by other authors 278 
and MRI findings in the current study it is suggested that the majority of dogs with eosinophilic MUO suffer from 279 
a diffuse cerebrocortical meningitis and cortical (polio)encephalitis which can be clearly identified on MRI 280 
(Smith-Maxie et al. 2008; Williams et al. 2008; Henke et al. 2009; Olivier et al. 2010). Although no 281 
histopathology was available for dogs in the current study it is hypothesized that MRI findings are due to migration 282 
of eosinophils via the meningeal vasculature into the meninges and cerebral cortex leading to an inflammatory 283 
response and neuronal necrosis in the cerebral cortex (Bennett et al. 1997; Smith-Maxie et al. 2008;). In other 284 
forms of non-infectious meningoencephalitides (granulomatous meningoencephalitis (GME), necrotising 285 
meningoencephalitis (NME), necrotising leukoencephalitis (NLE)) lesions reflect the neuropathologies associated 286 
with each disorder often with significant overlap between conditions (Talarico 2010). Consequently MR images 287 
are rarely pathognomonic with variables such as the presence or absence of necrosis, topographical distribution, 288 
mass effect and the level of meningeal contrast uptake allowing some differentiation between diseases (Coates 289 
2014, Talarico 2010). GME, NLE and NME frequently produce multifocal, asymmetrical, intraaxial lesions that 290 
variably affect grey and white matter. This is in contrast to MR images from the current study in which lesions 291 
are most often bilateral, symmetrical, limited to the cerebral cortex and associated with diffuse meningeal contrast 292 
uptake (Coates 2014, Talarico 2010). Other potential differential diagnoses for the bilateral cortical changes noted 293 
on MRI could include storage diseases such as neuronal ceroid lipofuscinosis (Nakamoto et al. 2011), canine 294 
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cognitive dysfunction (Hasegawa et al. 2005) or cerebrocortical necrosis secondary to metabolic or nutritional 295 
abnormalities (Singh et al. 2005, Dewey & da Costa 2016). However, the signalment of dogs in the current study, 296 
normal biochemical test results, CSF analysis demonstrating an eosinophilic pleocytosis and the specific nature 297 
of the MRI findings were not felt to be consistent with alternate differential diagnoses.  298 
 299 
The final dog in the current study had marked masticatory muscle atrophy, left facial nerve and trigeminal nerve 300 
dysfunction and an enlarged and contrast enhancing left trigeminal nerve on MRI (Table 1, Fig 3). There were 301 
also T2W and FLAIR hyperintense lesions within the muscle and mild patchy contrast uptake post-gadolinium 302 
administration on T1W images. Focal involvement of cranial nerves in dogs with eosinophilic MUO has 303 
previously been reported in a 4-year-old Golden Retriever and a 13-year-old German Shepherd Dog. As in the 304 
current study both dogs reported in the literature were the oldest in their respective studies (Smith-Maxie et al. 305 
2008; Windsor et al. 2009). Atrophy and MRI changes of masticatory muscles have been reported with conditions 306 
causing a focal myositis or neuritis affecting the trigeminal nerve including immune-mediated masticatory 307 
myositis, myositis or neuritis as a result of Neospora caninum, trauma, or neoplasms. Serum biochemistry and 308 
tests for infectious agents were negative making an infectious aetiology less likely. Further diagnostic tests that 309 
could have been performed to further exclude neoplastic or inflammatory/infectious differentials include muscle 310 
biopsy and histopathology, 2M antibody testing and fine needle aspirates of muscle or nerve (Cauduro et al. 2013; 311 
Dewey & da Costa 2016).  312 
 313 
Due to the small sample size and lack of histopathology it is challenging to draw robust conclusions on outcomes 314 
 20 
for dogs diagnosed with eosinophilic MUO. However in the current study the outcome is overall good, with over 315 
90% of dogs surviving to discharge and 75% of dogs, for which long-term follow-up was available, considered 316 
neurologically normal or markedly improved. It should be noted that for two dogs included in the survival analysis 317 
the follow-up time from diagnosis was 60 days or less (Case 3, Case 8) which may potentially bias the analysis 318 
of median survival time and highlights the need for a larger sample size in studies of this type. One dog died 319 
because of disease progression and a further two were euthanised as a result of persistent clinical signs which is 320 
similar to previous reports where 25% of dogs with eosinophilic MUO died or were euthanized because of the 321 
condition (Windsor et al. 2009). Only two of the 7 dogs for which follow-up was available were not receiving any 322 
treatment whilst the remaining 5 dogs received long-term low doses of prednisolone, cytarabine arabinoside or a 323 
combination of the two. While it is challenging to make direct comparisons with treatment protocols used in other 324 
forms of MUO the outcome data in this study compare favorably to other non-infectious meningoencephalitides 325 
where mortality rates are as high as 26% in the first week following diagnosis (Cornelis, Volk & De Decker 2016; 326 
Cornelis et al. 2016). The good response to long-term immunosuppressive drugs observed in many dogs with 327 
eosinophilic MUO, and no evidence of infectious disease, further supports an underlying immune-mediated 328 
condition that may be affecting cortical neurons (Windsor et al. 2009; Talarico & Schatzberg 2010). It is of note 329 
that in the single dog that had follow up MRI 1173 days after diagnosis the MRI findings had shown a significant 330 
progression, including worsening cortical atrophy and ventriculomegaly, despite a normal CSF sample (Fig 4). 331 
This suggests that the cortical damage caused by eosinophilic MUO is permanent and potentially progressive 332 
despite effective treatment of the disease as determined by CSF sampling.  333 
 334 
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This study is limited by its retrospective nature and the small number of included cases preventing robust 335 
conclusions being drawn on outcomes and prognostic indicators for dogs with eosinophilic MUO. To date no 336 
dogs have been available for post-mortem examination due to the small number of cases and the relatively 337 
favourable outcomes following immunosuppressive treatment. A key area of future work is to obtain 338 
histopathology to corroborate MRI findings and gain a better understanding of the underlying pathology of 339 
eosinophilic MUO.  340 
 341 
To the best of the authors’ knowledge, this is the first study describing clinical, imaging and outcome data for a 342 
series of dogs with eosinophilic MUO. The majority (83%) of eosinophilic MUO cases present as a severe diffuse 343 
cerebrocortical meningitis and cortical encephalitis which can be clearly identified on MRI. Seventy five percent 344 
of dogs in this study have a favorable response to immunosuppressive therapy in the medium to long term. These 345 
distinct MRI findings may serve as an aid in the diagnosis of eosinophilic MUO in dogs.  346 
  347 
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Figure Legends: 348 
Fig 1. Dog 7: Transverse magnetic resonance images at the level of the interthalamic adhesion (a,b,c,d) showing 349 
a T2W hyperintense (a) to grey matter, FLAIR hyperintense (b) and T1W iso/hypointense (c) signal bilaterally 350 
affecting the sub-meningeal cortical grey matter (white asterisks). Cerebral sulci appeared grossly enlarged with 351 
a reduction in the size of the cortical gyri (a,c). Post-gadolinium contrast administration there was moderate diffuse 352 
contrast uptake affecting both the pachymeninges and leptomeninges (c,d) (white arrows). Mild ventricular 353 
enlargement is also evident (black asterisk).  354 
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Fig 2. Dog 9: Transverse magnetic resonance images at the level of the thalamus (a,b,c,d) showing masticatory 355 
muscle atrophy (white arrow) with regions of T2W and FLAIR hyperintensity within the masseter and temporalis 356 
muscles which showed moderate contrast uptake. The left trigeminal nerve was T2W and FLAIR hyperintense 357 
compared to the right side, subjectively enlarged and showed mild homogenous contrast enhancement (white 358 
asterisk). 359 
  
  
 360 
  361 
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Fig 3. Dog 6: Sagittal midline (a, c) and transverse magnetic resonance images at the level of the thalamus (b, d) 362 
demonstrating increased T2W hyperintense to normal grey matter signal bilaterally affecting the sub-meningeal 363 
cortical grey matter, increased ventriculomegaly (black asterisk) and a reduction in size of the interthalamic 364 
adhesion (white asterisk) when images at 1173 days after diagnosis (c, d) are compared to those taken at the time 365 
of diagnosis (a, b). 366 
  
  
  367 
Table 1: Summary of clinical presentation, MRI findings and treatment outcomes of dogs diagnosed with suspected eosinophilic meningoencephalitis of unknown origin 
 
No. Breed Weight 
(kg) 
Age 
(mths) 
Sex / 
Neuter 
TTP 
(days) 
Previous 
treatment 
Neurological examination 
(abnormal findings stated) 
Neuro-
anatomical 
localisation 
WBC 
(x10^9/l) 
Blood 
Eos 
(x10^9/l) 
 
 (%) 
CSF  
TNCC 
(mm3) 
 
(%) 
CSF 
Protein 
(mg/dl) 
MRI findings Treatment  
(at time of data 
capture)b 
Outcome  
(survival 
since 
diagnosis) 
1 Flat-Coated 
Retriever 
31.0 34 M 24 None Obtunded, reduced paw 
positioning pelvic limbs, reduced 
menace response (OU), blind.  
Diffuse forebrain 10.90 2.07 
 
(19%) 
222 
 
(78%) 
0.33 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
Prednisolone 
2mg/kg/day 
Euthanised 
(remained 
blind) 
(31 days) 
2 Jack 
Russell 
Terrier 
8.9 25 M 78 Prednisolone 
(Tapering to 
0.35mg/kg PO 
SID, 90 days) 
Obtunded, reduced paw 
positioning all limbs, reduced 
menace response (OU), reduced 
PLR (OU), generalised ataxia, 
blind 
Multifocal brain 27.10 0.20 
 
(2%) 
6 
 
(12%) 
0.21 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
None Alive 
 
(3631 days) 
3 Rottweiler 36.0 12 M 14 None Obtunded, reduced menace 
response (OU), reduced PLR 
(OU), generalised ataxia, cervical 
hyperaesthesia, blind 
Multifocal brain 9.00 2.07 
 
(23%) 
1,005 
 
(90%) 
0.73 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
Prednisolone 
1.5mg/kg/day 
 
Lost to follow 
up at 60 days 
4 Bichon 
Frise 
9.1 23 MN 8 None Obtunded, vestibular ataxia 
(falling to left), positional vertical 
nystagmus 
Central vestibular 
system 
15.20 3.81 
 
(25%) 
1,839 
 
(93%) 
0.97 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
None  Alive 
 
(1642 days) 
5 Welsh 
Terrier 
7.7 11 F 32 None Seizures, obtunded, absent paw 
positioning pelvic limbs, absent 
menace response (OU), vestibular 
ataxia (falling to right) 
Central vestibular 
system 
11.09 0.91 
 
(12%) 
542 
 
(76%) 
0.52 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
Cytarabine 
arabinoside: 
every 8 weeks  
Alive 
 
(1173 days) 
6 Welsh 
Terrier 
10.3 17 M 8 None Obtunded, reduced paw 
positioning all limbs, reduced 
menace response (OU), 
generalised ataxia, cervical 
hyperaesthesia 
Multifocal brain 12.81 1.55 
 
(10%) 
837 
 
(85%) 
0.38 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
Cytarabine 
arabinoside: 
every 8 weeks 
Alive  
 
(820 days) 
7 Cross breed 4.9 18 FS 36 None Obtunded, absent paw positioning 
all limbs, absent menace response 
(OU), vestibular ataxia, positional 
vertical nystagmus, cervical 
hyperaesthesia, blind 
Central vestibular 
system 
7.36 1.41 
 
(15%) 
16 
 
(80%) 
0.15 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
Prednisolone 
0.5mg/kg every 
other day. 
Alive  
 
(214 days) 
8 Kerry Blue 
Terrier 
22.0 99 MN 44 Prednisolone 
(0.5mg/kg/day, 
34 days. Stopped 
8 days prior to 
presentation) 
Absent corneal and facial 
sensation (left), absent palpebral 
reflex (left), left masticatory 
muscle atrophy 
Left trigeminal 
and facial nerves 
(or their nuclei) 
11.41 2.17 
 
(19%) 
5,400 
 
(91%) 
1.06 Left masticatory muscle atrophy with 
moderate contrast uptake 
Enlarged left trigeminal nerve with 
contrast uptake  
Prednisolone 
2mg/kg/day 
 
Cytarabine 
arabinoside: 
every 3 weeks 
Alive  
 
(57 days) 
9 Boxer 26.0 26 F 62 None Obtunded, reduced menace 
response (OU), generalised ataxia, 
cervical hyperaesthesia 
Multifocal brain 7.33 1.39 
 
(19%) 
4,960 
 
(86%) 
0.93 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
Prednisolone 
1mg/kg/day 
 
Cytarabine 
arabinoside: 
every 3 weeks 
Alive 
 
(120 days) 
10a Flat-Coated 
Retriever 
32.4 22 F 23 None Seizures, obtunded, reduced paw 
positioning pelvic limbs, absent 
menace response (OU), blind 
Diffuse forebrain 12.09 1.62 
 
(14%) 
451 
 
(95%) 
0.7 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
None  Lost to 
follow-up 732 
days 
11a Belgian 
Shepherd 
Dog 
(Tervueren) 
18.0 7 F 2 Prednisolone 
(0.9mg/kg/day, 1 
day) 
Obtunded, absent paw positioning 
all limbs, absent menace response 
(OU), ataxia, positional vertical 
nystagmus, blind. 
Central vestibular 
system 
13.60 1.73 
 
(13%) 
671 
 
(85%) 
0.76 T2W and FLAIR hyperintense signal 
affecting cortical grey matter 
Cerebral sulci enlarged 
Meningeal contrast uptake 
N/A Died  
 
(1 day) 
a Ghent University 
b all Cytarabine arabinoside doses: 50 mg/m2 SC every 12 h for 2 consecutive days 
 
BID: Twice daily, Eos: Eosinophils, F: Female entire, FS: Female spayed, IHC: Immunohistochemistry, M: male entire, MN: Male neutered, N/A: Not available, OU: Oculus uterque, PLR: 
pupillary light reflex, TID: every 8 hours, TNCC: Total nucleated cell count, TTP: time to presentation (time from clinical signs first being noticed by owner to diagnosis), WNL: Within 
normal limits. 
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